<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE patent-application-publication SYSTEM "pap-v16-2002-01-01.dtd" []>
<patent-application-publication>
<subdoc-bibliographic-information>
<document-id>
<doc-number>20030003536</doc-number>
<kind-code>A1</kind-code>
<document-date>20030102</document-date>
</document-id>
<publication-filing-type>new</publication-filing-type>
<domestic-filing-data>
<application-number>
<doc-number>10128853</doc-number>
</application-number>
<application-number-series-code>10</application-number-series-code>
<filing-date>20020423</filing-date>
</domestic-filing-data>
<foreign-priority-data>
<priority-application-number>
<doc-number>9907097.1</doc-number>
</priority-application-number>
<filing-date>19990326</filing-date>
<country-code>GB</country-code>
</foreign-priority-data>
<technical-information>
<classification-ipc>
<classification-ipc-primary>
<ipc>C07K014/705</ipc>
</classification-ipc-primary>
<classification-ipc-secondary>
<ipc>C07H021/04</ipc>
</classification-ipc-secondary>
<classification-ipc-secondary>
<ipc>C12P021/02</ipc>
</classification-ipc-secondary>
<classification-ipc-secondary>
<ipc>C12N005/06</ipc>
</classification-ipc-secondary>
<classification-ipc-edition>07</classification-ipc-edition>
</classification-ipc>
<classification-us>
<classification-us-primary>
<uspc>
<class>435</class>
<subclass>069100</subclass>
</uspc>
</classification-us-primary>
<classification-us-secondary>
<uspc>
<class>435</class>
<subclass>325000</subclass>
</uspc>
</classification-us-secondary>
<classification-us-secondary>
<uspc>
<class>435</class>
<subclass>320100</subclass>
</uspc>
</classification-us-secondary>
<classification-us-secondary>
<uspc>
<class>530</class>
<subclass>350000</subclass>
</uspc>
</classification-us-secondary>
<classification-us-secondary>
<uspc>
<class>536</class>
<subclass>023500</subclass>
</uspc>
</classification-us-secondary>
</classification-us>
<title-of-invention>Vanilloid receptor</title-of-invention>
</technical-information>
<continuity-data>
<continuations>
<continuation-of>
<parent-child>
<child>
<document-id>
<doc-number>10128853</doc-number>
<kind-code>A1</kind-code>
<document-date>20020423</document-date>
</document-id>
</child>
<parent>
<document-id>
<doc-number>09533220</doc-number>
<document-date>20000323</document-date>
<country-code>US</country-code>
</document-id>
</parent>
<parent-status>GRANTED</parent-status>
<parent-patent>
<document-id>
<doc-number>6406908</doc-number>
<country-code>US</country-code>
</document-id>
</parent-patent>
</parent-child>
</continuation-of>
</continuations>
</continuity-data>
<inventors>
<first-named-inventor>
<name>
<given-name>Peter</given-name>
<family-name>McIntyre</family-name>
</name>
<residence>
<residence-non-us>
<city>London</city>
<country-code>GB</country-code>
</residence-non-us>
</residence>
<authority-applicant>INV</authority-applicant>
</first-named-inventor>
<inventor>
<name>
<given-name>Iain</given-name>
<middle-name>Fraser</middle-name>
<family-name>James</family-name>
</name>
<residence>
<residence-non-us>
<city>London</city>
<country-code>GB</country-code>
</residence-non-us>
</residence>
<authority-applicant>INV</authority-applicant>
</inventor>
</inventors>
<correspondence-address>
<name-1>THOMAS HOXIE</name-1>
<name-2>NOVARTIS CORPORATION</name-2>
<address>
<address-1>PATENT AND TRADEMARK DEPT</address-1>
<address-2>564 MORRIS AVENUE</address-2>
<city>SUMMIT</city>
<state>NJ</state>
<postalcode>079011027</postalcode>
</address>
</correspondence-address>
</subdoc-bibliographic-information>
<subdoc-abstract>
<paragraph id="A-0001" lvl="0">The isolated nucleic acid encoding human vanilloid receptor, said receptor, its preparation, cells expressing said receptor and an assay for testing compounds for their potential to decrease pain in humans. The receptor is involved in detection of noxious stimuli in mammalian organisms. </paragraph>
</subdoc-abstract>
<subdoc-description>
<summary-of-invention>
<paragraph id="P-0001" lvl="0"><number>&lsqb;0001&rsqb;</number> The present invention is directed to an isolated nucleic acid encoding human vanilloid receptor, said receptor, its preparation, cells expressing said receptor and an assay for testing compounds for their potential to decrease pain in humans. </paragraph>
<paragraph id="P-0002" lvl="0"><number>&lsqb;0002&rsqb;</number> More particularly the present invention provides in a first aspect, an isolated nucleic acid encoding a human vanilloid receptor. </paragraph>
<paragraph id="P-0003" lvl="0"><number>&lsqb;0003&rsqb;</number> Even more particularly the present invention provides an isolated nucleic acid capable of directing expression of a human vanilloid receptor, in particular a cDNA capable of directing expression of said receptor, more particularly a cDNA comprising the nucleotide sequence as depicted in SEQ ID NO: 1, most particularly a cDNA capable of directing expression of the predicted protein depicted in SEQ ID NO: 2. </paragraph>
<paragraph id="P-0004" lvl="0"><number>&lsqb;0004&rsqb;</number> Said isolated nucleic acid may have a nucleotide sequence having sequence identity within a range of from more than 85.5%, preferably more than 97% to 100% over the open reading frame with the nucleotide sequence as described in SEQ ID NO: 1. Preferably said isolated nucleic acid comprises a nucleic acid identical over the open reading frame to the sequence as described in SEQ ID NO: 1. </paragraph>
<paragraph id="P-0005" lvl="0"><number>&lsqb;0005&rsqb;</number> The nucleic acid may be prepared for example by constructing a cDNA library from mRNA derived from human neuronal cells expressing vanilloid receptor. Such cells may be the nociceptive neurones, the cell bodies thereof residing within the dorsal root ganglia. The cDNA may then be expressed in a cell line not normally expressing endogenous vanilloid receptor and by iteratively subdividing and reassaying positive clones an individual clone may be obtained comprising the desired nucleic acid. </paragraph>
<paragraph id="P-0006" lvl="0"><number>&lsqb;0006&rsqb;</number> In a further embodiment the present invention is directed to a recombinant human vanilloid receptor. An example for said human vanilloid receptor may be a protein encoded by a nucleic acid having sequence identity within a range of from more than 85.5%, preferably more than 97% to 100% over the open reading frame with the nucleotide sequence as described in SEQ ID NO: 1, e.g. a protein comprising an amino acid sequence having sequence identity within a range of from more than 85.7% to 100% with the amino acid sequence as described in SEQ ID NO: 2, as calculated using the ALIGN program &lsqb;Myers and Miller, CABIOS (1989)&rsqb;. The amino acid differences may occur at a site selected from the N-terminus, the C-terminus and the putative pore region of the channel, i.e. amino acid 597 to amino acid 696 of SEQ ID NO: 2. Preferably the human vanilloid receptor comprises an amino acid sequence identical to the sequence as described in SEQ ID NO: 2. </paragraph>
<paragraph id="P-0007" lvl="0"><number>&lsqb;0007&rsqb;</number> The human vanilloid receptor when expressed in mammalian cells is activated by capsaicin, temperatures greater than 42&deg; C. and by pH less than 5.5. The activation by all these effectors can be blocked substantially or completely by the action of the capsaicin antagonist capsazepine. </paragraph>
<paragraph id="P-0008" lvl="0"><number>&lsqb;0008&rsqb;</number> The vanilloid receptor may be prepared by stably transfecting a cell line with an appropriate expression cassette comprising a nucleic acid encoding the receptor, and culturing cells of said cell line under conditions which allow expression of said receptor. </paragraph>
<paragraph id="P-0009" lvl="0"><number>&lsqb;0009&rsqb;</number> In a further embodiment the present invention is directed to a cell belonging to a cell line expressing recombinant human vanilloid receptor. </paragraph>
<paragraph id="P-0010" lvl="0"><number>&lsqb;0010&rsqb;</number> In a further embodiment the present invention is directed to a cell belonging to a cell line expressing recombinant mammalian vanilloid receptor and aequorin. </paragraph>
<paragraph id="P-0011" lvl="0"><number>&lsqb;0011&rsqb;</number> Examples for useful cell lines include any cell line growing well in culture, e.g. human embryonic kidney derived cells, like HEK293 cells and Chinese hamster ovary cells, like CHO-DUKX-B11 cells &lsqb;Kaufman et al., Mol. Cell biol. 5:1750-1759 (1985)&rsqb;, which have been transformed/transfected with an appropriate expression cassette comprising a nucleic acid encoding human or mammalian vanilloid receptor and optionally a nucleic acid encoding aequorin. The expression cassette may be derived from a vector selected from for example pIRESneo, pBKCMV and pXMT3. A very useful cell line is the CHO-DUKX-B11 cell line. </paragraph>
<paragraph id="P-0012" lvl="0"><number>&lsqb;0012&rsqb;</number> Examples for a mammalian vanilloid receptor are the rat receptor and the human receptor. </paragraph>
<paragraph id="P-0013" lvl="0"><number>&lsqb;0013&rsqb;</number> Aequorin is a protein from the jellyfish. In the presence of Ca<highlight><superscript>&plus;&plus;</superscript></highlight> ions the complex of aequorin and coelenterazine gives off light. </paragraph>
<paragraph id="P-0014" lvl="0"><number>&lsqb;0014&rsqb;</number> In a further embodiment the present invention is directed to an assay to measure vanilloid receptor activation comprising measuring changes in aequorin luminescence of cells expressing a mammalian vanilloid receptor and aequorin. </paragraph>
<paragraph id="P-0015" lvl="0"><number>&lsqb;0015&rsqb;</number> In a further embodiment the present invention is directed to a screening assay for vanilloid receptor channel blockers comprising incubation of a cell expressing a mammalian vanilloid receptor and aequorin with the potential vanilloid receptor channel blocker, adding an activator/agonist, e.g. capsaicin, of the vanilloid receptor channel and measuring changes in aequorin luminescence. </paragraph>
<paragraph id="P-0016" lvl="0"><number>&lsqb;0016&rsqb;</number> In a further embodiment the present invention is directed to a screening assay for vanilloid receptor channel agonists comprising incubation of a cell expressing a mammalian vanilloid receptor and aequorin, adding the potential vanilloid receptor channel agonist and measuring changes in aequorin luminescence. </paragraph>
<paragraph id="P-0017" lvl="0"><number>&lsqb;0017&rsqb;</number> In a further embodiment the present invention is directed to an assay to measure vanilloid receptor activation comprising measuring changes in the fluorescence of laser activated, calcium sensitive dyes, e.g. fura 2 AM and fluo3. </paragraph>
<paragraph id="P-0018" lvl="0"><number>&lsqb;0018&rsqb;</number> In a further embodiment the present invention is-directed to a screening assay for vanilloid receptor channel blockers comprising incubation of a cell expressing a mammalian vanilloid receptor and optionally aequorin with the potential vanilloid receptor channel blocker, adding an activator/agonist, e.g. capsaicin, of the vanilloid receptor and measuring changes in the fluorescence of laser activated, calcium sensitive dyes, e.g. fura 2 AM and fluo 3. </paragraph>
<paragraph id="P-0019" lvl="0"><number>&lsqb;0019&rsqb;</number> In a further embodiment the present invention is directed to a screening assay for vanilloid receptor channel agonists comprising incubation of a cell expressing a mammalian vanilloid receptor and optionally aequorin with the potential vanilloid receptor channnel agonist and measuring changes in the fluorescence of laser activated, calcium sensitive dyes, e.g. fura 2 AM and fluo3. </paragraph>
<paragraph id="P-0020" lvl="0"><number>&lsqb;0020&rsqb;</number> The above assay formats allow automation and are suitable for screening. </paragraph>
<paragraph id="P-0021" lvl="0"><number>&lsqb;0021&rsqb;</number> In a further embodiment the present invention is directed to a novel vanilloid receptor channel blocker identified by a screening assay for vanilloid receptor channel blockers comprising incubation of a cell expressing a mammalian vanilloid receptor and aequorin with the potential vanilloid receptor channel blocker, adding an activator/agonist, e.g. capsaicin, of the vanilloid receptor and measuring changes in aequorin luminescence. </paragraph>
<paragraph id="P-0022" lvl="0"><number>&lsqb;0022&rsqb;</number> In a further embodiment the present invention is directed to a novel vanilloid receptor channel agonist identified by a screening assay for vanilloid receptor channel agonists comprising incubation of a cell expressing a mammalian vanilloid receptor and aequorin with the potential vanilloid receptor channel agonist and measuring changes in aequorin luminescence. </paragraph>
<paragraph id="P-0023" lvl="0"><number>&lsqb;0023&rsqb;</number> In a further embodiment the present invention is directed to a novel vanilloid receptor channel blocker identified by a screening assay for vanilloid receptor channel blockers comprising incubation of a cell expressing a mammalian vanilloid receptor and optionally aequorin with the potential vanilloid receptor channel blocker, adding an activator/agonist, e.g. capsaicin, of the vanilloid receptor and measuring changes in the fluorescence of laser activated, calcium sensitive dyes, e.g. fura 2 AM and fluo3. </paragraph>
<paragraph id="P-0024" lvl="0"><number>&lsqb;0024&rsqb;</number> In a further embodiment the present invention is directed to a novel vanilloid receptor channel agonist identified by a screening assay for vanilloid receptor channel agonists comprising incubation of a cell expressing a mammalian vanilloid receptor and optionally aequorin with the potential vanilloid receptor channel agonist and measuring changes in the fluorescence of laser activated, calcium sensitive dyes, e.g. fura 2 AM and fluo3. </paragraph>
<paragraph id="P-0025" lvl="0"><number>&lsqb;0025&rsqb;</number> In accordance with the foregoing the present invention also provides: </paragraph>
<paragraph id="P-0026" lvl="1"><number>&lsqb;0026&rsqb;</number> (1) an isolated nucleic acid encoding a human vanilloid receptor; </paragraph>
<paragraph id="P-0027" lvl="1"><number>&lsqb;0027&rsqb;</number> (2) a recombinant human vanilloid receptor; </paragraph>
<paragraph id="P-0028" lvl="1"><number>&lsqb;0028&rsqb;</number> (3) a method of preparation of the receptor of (2); </paragraph>
<paragraph id="P-0029" lvl="1"><number>&lsqb;0029&rsqb;</number> (4) a cell line expressing the receptor of (2) and optionally aequorin; </paragraph>
<paragraph id="P-0030" lvl="1"><number>&lsqb;0030&rsqb;</number> (5) an assay to measure vanilloid receptor activation; </paragraph>
<paragraph id="P-0031" lvl="1"><number>&lsqb;0031&rsqb;</number> (6) a screening assay for vanilloid receptor channel blockers or agonists; and </paragraph>
<paragraph id="P-0032" lvl="1"><number>&lsqb;0032&rsqb;</number> (7) novel vanilloid receptor channel blocker or agonist, e.g. obtained via (6).</paragraph>
</summary-of-invention>
<detailed-description>
<paragraph id="P-0033" lvl="0"><number>&lsqb;0033&rsqb;</number> The following examples illustrate the invention without limitation. The following abbreviations are used in the examples: DRG: dorsal root ganglion; G418: Geneticin; HBSS: Hanks balanced salt solution; PBS: phosphate buffered saline; RT: room temperature; VR: vanilloid receptor </paragraph>
<section>
<heading lvl="1">EXAMPLE A1 </heading>
</section>
<section>
<heading lvl="1">Preparation of CHO Cells Expressing Rat VR and Aequorin </heading>
<paragraph id="P-0034" lvl="1"><number>&lsqb;0034&rsqb;</number> (a) Aequorin-pXMT3: The pXMT3 mammalian expression plasmid, SEQ ID NO: 3, encodes a cDNA for dihydrofolate reductase. Aequorin-pBk-CMV (SEQ ID NO: 4) is linearised with Nhe1 (immediately upstream of the Kozak consensus sequence). The 5&prime;overhang is filled in with Klenow fragment and phosphorylated PstI linker (New England Biolabs) is blunt end ligated to the DNA. The aequorin insert is released with PstI and EcoRI and cloned into pXMT3. </paragraph>
<paragraph id="P-0035" lvl="1"><number>&lsqb;0035&rsqb;</number> (b) Cloning of rVR1: A rat vanilloid receptor, rVR1, cDNA is cloned by homology cloning from a rat DRG cDNA library in lambda ZAP express using a 969 bp PCR fragment corresponding to nucleotides 1513 to 2482 from the rat VR1 sequence &lsqb;Caterina et al., Nature 389:816-824 (1997)&rsqb; as a probe. This probe is derived by RT-PCR using RNA from adult rat DRG &lsqb;Helliwell et al., Neuroscience Lett. 250:177-180 (1998). The rVR1 insert is then cut out with EcoR1 and Not1 and then subcloned into the pIRESneo expression vector (Accession Number U89673) (Clontech).The rVR1 PCR clone is then subcloned into pcDNA3.1 (Invitrogen) expression vector. DNA used for transient and stable transfections is purified using Promega&apos;s Wizard plus Maxi or Megaprep DNA purification systems. </paragraph>
<paragraph id="P-0036" lvl="1"><number>&lsqb;0036&rsqb;</number> (c) Production of rVR1/aequorin CHO cell stable clone: DUKX-CHO-Aequorin cells which have previously been transfected with pXMT3-aequorin are transfected with plRESneo-rVR1 using LipofectAMINE PLUS reagent. 1,000,000 cells are transfected with 1.25 &mgr;g of rVR1 DNA. 2 days following transfectection 700 &mgr;g/ml G418 is used to select for positive cells. Transfected cells are visible after 5 days and continued to be grown in the presence of G418 after that. 10 days later the G418 selected cells are cloned by limiting dilution in 96 well plates and continue to be grown in G418 after that. </paragraph>
</section>
<section>
<heading lvl="1">EXAMPLE A2 </heading>
</section>
<section>
<heading lvl="1">Preparation of CHO Cells Expressing Human VR and Aequorin </heading>
<paragraph id="P-0037" lvl="1"><number>&lsqb;0037&rsqb;</number> (a) Cloning of hVR1: A human DRG cDNA library of approximately 80,000 clones is made in lambda ZAP express using a Stratagene kit. The library is screened at low stringency (2&times;SSC, 45&deg; C.) using the rat VR1 probe described in Example A1. Several clones are isolated and the longest full-length one, clone 3D, is chosen for expression studies (SEQ ID NO: 1). The insert is cut out with Eco R1 and Not 1 and cloned into plRESneo (Accession Number U89673) (Clontech). </paragraph>
<paragraph id="P-0038" lvl="1"><number>&lsqb;0038&rsqb;</number> (b) Production of hVR1/Aequorin CHO cell stable clone: DUKX-CHO-Aequorin cells which have previously been transfected with pXMT3-aequorin are transfected with plRESneo-hVR1 using LipofectAMINE PLUS reagent. 1,000,000 cells are transfected with 1.25 &mgr;g of hVR1 DNA. 2 days following transfection 700 &mgr;g/ml G418 is used to select for positive cells. Transfected cells are visible after 5 days and later, the G418 selected cells are cloned by limiting dilution in 96 well plates and continue to be grown in the presence of G418 after that. </paragraph>
</section>
<section>
<heading lvl="1">EXAMPLE B1 </heading>
</section>
<section>
<heading lvl="1">Potency of Capsaicin (Agonist) </heading>
<paragraph id="P-0039" lvl="1"><number>&lsqb;0039&rsqb;</number> (a) Calcium uptake assay: Primary cultures of adult DRG neurones are prepared according to standard protocols &lsqb;Wood et al., J. Neuroscience 8:3208-3220 (1988)&rsqb;. Cells are plated at a density of 2000 per well on 96 well view plates pre-coated with poly-ornithine and laminin and cultured in Hams F14 supplemented with 100 ng/ml NGF for four days. On the day of the assay, the cells are washed eight times in a Denley cell washer with calcium/magnesium free HBSS plus 10 mM HEPES, pH7.4. After washing the wells contain approximately 75 &mgr;l of buffer. </paragraph>
<paragraph id="P-0040" lvl="1"><number>&lsqb;0040&rsqb;</number> To this is added 25 &mgr;l of capsaicin with or without capsazepine or ruthenium red in Ca/Mg free buffer containing 370 KBq of <highlight><superscript>45</superscript></highlight>Ca<highlight><superscript>2&plus;</superscript></highlight>/ml. For negative control, capsaicin is omitted. Samples are incubated at RT for 10 min, then washed four times with HBSS/10 mM HEPES pH 7.4. The remaining buffer is removed from the wells and replaced with 25 &mgr;l of 0.1% SDS. After about 10 min 200 &mgr;l of Microscint 40 scintillant is added and samples are counted on a Packard Topcount. </paragraph>
<paragraph id="P-0041" lvl="1"><number>&lsqb;0041&rsqb;</number> (b) Measurement of aequorin activity: Active aequorin is reconstituted by incubating confluent cells resulting from Examples A1 or A2 at 37&deg; C. with 20 &mgr;M coelenterazine h &lsqb;Biochem. J. 261:913-920 (1989)&rsqb; and 30 &mgr;M glutathione (reduced form) in 50 &mgr;l of medium per well. All the plates for use in a day are set up at the same time. The first plate is used in the assay after 2.5 h incubation with coelenterazine h. Subsequent plates are used at about 10 min intervals. There is no loss of signal with the longer incubation times. At the start of the assay, the medium containing coelenterazine h is removed and replaced with 100 &mgr;l of HBSS buffered to pH 7.4 with 10 mM HEPES containing test compounds where appropriate. Cells are incubated for at least 10 min at RT. They are then placed in the measuring chamber of a luminometer (Wallac Microbeta Jet). Agonist is injected in a volume of 20 &mgr;l HBSS and the luminescence signal is collected for 20 sec. </paragraph>
<paragraph id="P-0042" lvl="1"><number>&lsqb;0042&rsqb;</number> (c) Fluorometric assay using the FLIPR: Cells resulting from Examples A1 or A2 are plated at a density of 50,000 cells/well in Costar Viewplates. The cells are incubated at 37&deg; C. in a humidified atmosphere (5% CO<highlight><subscript>2</subscript></highlight>/95% air) for 24 h. Medium is removed by flicking the plates and replaced with 100 &mgr;l HBSS containing 2 &mgr;M Fluo-3, AM (Molecular Probes) in the presence of 2.5 mM probenicid (Sigma) and 0.02% pluronic acid (Molecular Probes). The cells are incubated at 37&deg; C. in a humidified atmosphere (5% CO<highlight><subscript>2</subscript></highlight>/95% air) for 1 h. Plates are flicked to remove excess of Fluo-3, AM, washed twice with HBSS and refilled with 100 &mgr;l of HBSS containing screening compounds. Incubation in the presence of screening compounds lasts between 10 and 20 min. Plates are then placed in the cell plate stage of the FLIPR (Molecular Devices, Sunnyvale, Calif., USA). A baseline consisting in 5 measurements of 0.4 sec each (laser: excitation 488 nm at 0.6 W, CCD camera opening of 0.4 sec) is recorded. Capsaicin (50 &mgr;l at 45 nM) is added from the agonist plate (placed in the agonist plate stage of the FLIPR tower) to the cell plate using the FLIPR 96-tip pipettor simultaneously to fluorescence recording for 3 min according to the following scheme: 0.4 sec measurements each interval of 1 sec for 1 min followed by 0.4 sec measurements each interval of 4 sec for 100 sec. Data are expressed as (Fm&minus;Fb)/Fb where Fm is the fluorescence peak reached following capsaicin injection and Fb is the baseline fluorescence prior to capsaicin injection.  
<table-cwu id="TABLE-US-00001">
<number>1</number>
<table frame="none" colsep="0" rowsep="0">
<tgroup align="left" colsep="0" rowsep="0" cols="3">
<colspec colname="1" colwidth="84PT" align="center"/>
<colspec colname="2" colwidth="70PT" align="center"/>
<colspec colname="3" colwidth="63PT" align="center"/>
<tbody valign="top">
<row>
<entry></entry>
</row>
<row><entry namest="1" nameend="3" align="center" rowsep="1"></entry>
</row>
<row>
<entry>EC<highlight><subscript>50 </subscript></highlight>(nM)</entry>
<entry></entry>
<entry></entry>
</row>
<row>
<entry>(aequorin assay)</entry>
<entry>EC<highlight><subscript>50 </subscript></highlight>(nM)</entry>
<entry>EC<highlight><subscript>50 </subscript></highlight>(nM)</entry>
</row>
</tbody>
</tgroup>
<tgroup align="left" colsep="0" rowsep="0" cols="4">
<colspec colname="1" colwidth="42PT" align="center"/>
<colspec colname="2" colwidth="42PT" align="center"/>
<colspec colname="3" colwidth="70PT" align="center"/>
<colspec colname="4" colwidth="63PT" align="center"/>
<tbody valign="top">
<row>
<entry>rVR1 in</entry>
<entry>hVR1 in</entry>
<entry>(Ca uptake assay)</entry>
<entry>(Fluo-3 assay)</entry>
</row>
<row>
<entry>CHO cells</entry>
<entry>CHO cells</entry>
<entry>Rat DRG neurones</entry>
<entry>hVR1 in CHO cells</entry>
</row>
<row><entry namest="1" nameend="4" align="center" rowsep="1"></entry>
</row>
<row>
<entry>530 &plusmn; 100</entry>
<entry>480 &plusmn; 64</entry>
<entry>170 &plusmn; 19</entry>
<entry>3.42 &plusmn; 0.2</entry>
</row>
<row><entry namest="1" nameend="4" align="center" rowsep="1"></entry>
</row>
</tbody>
</tgroup>
</table>
</table-cwu>
</paragraph>
</section>
<section>
<heading lvl="1">EXAMPLE B2 </heading>
</section>
<section>
<heading lvl="1">Capsazepine and Ruthenium Red Activity on Vanilloid Receptors Activated by Capsaicin </heading>
<paragraph id="P-0043" lvl="1"><number>&lsqb;0043&rsqb;</number> (a) Inhibition of capsaicin responses by the competitive antagonist, capsazepine, is measured as described in Example B1. Capsaicin is used at a concentration of 1 &mgr;M. The IC<highlight><subscript>50 </subscript></highlight>for capsazepine at hVR1 is comparable to that at rVR1 and slightly lower than that measured in calcium uptake assays with DRG neurones. </paragraph>
<paragraph id="P-0044" lvl="1"><number>&lsqb;0044&rsqb;</number> (b) Activity of the channel blocker ruthenium red is measured as described in Example B1. The layout and conditions are the same as for (a) above. Ruthenium red is an effective blocker of capsaicin responses. The IC<highlight><subscript>50 </subscript></highlight>at hVR1 is slightly higher than at the cloned rVR1 or that found in the calcium uptake assay with primary cultures of DRG neurones.  
<table-cwu id="TABLE-US-00002">
<number>2</number>
<table frame="none" colsep="0" rowsep="0">
<tgroup align="left" colsep="0" rowsep="0" cols="4">
<colspec colname="OFFSET" colwidth="28PT" align="left"/>
<colspec colname="1" colwidth="70PT" align="center"/>
<colspec colname="2" colwidth="63PT" align="center"/>
<colspec colname="3" colwidth="56PT" align="center"/>
<tbody valign="top">
<row>
<entry></entry>
<entry></entry>
</row>
<row>
<entry></entry>
<entry namest="OFFSET" nameend="3" align="center" rowsep="1"></entry>
</row>
<row>
<entry></entry>
<entry>IC<highlight><subscript>50 </subscript></highlight>(nM)</entry>
<entry></entry>
<entry></entry>
</row>
<row>
<entry></entry>
<entry>(aequorin assay)</entry>
<entry>IC<highlight><subscript>50 </subscript></highlight>(nM)</entry>
<entry>IC<highlight><subscript>50 </subscript></highlight>(nM)</entry>
</row>
</tbody>
</tgroup>
<tgroup align="left" colsep="0" rowsep="0" cols="5">
<colspec colname="1" colwidth="28PT" align="center"/>
<colspec colname="2" colwidth="35PT" align="center"/>
<colspec colname="3" colwidth="35PT" align="center"/>
<colspec colname="4" colwidth="63PT" align="center"/>
<colspec colname="5" colwidth="56PT" align="center"/>
<tbody valign="top">
<row>
<entry>Com- </entry>
<entry>rVR1</entry>
<entry>hVR1</entry>
<entry>(Ca uptake assay)</entry>
<entry>(Fluo-3 assay)</entry>
</row>
<row>
<entry>pound</entry>
<entry>(CHO)</entry>
<entry>(CHO)</entry>
<entry>Rat DRG neurones</entry>
<entry>hVR1 CHO</entry>
</row>
<row><entry namest="1" nameend="5" align="center" rowsep="1"></entry>
</row>
<row>
<entry>Cz</entry>
<entry>320 &plusmn; 110</entry>
<entry>120 &plusmn; 12</entry>
<entry>800 &plusmn; 40</entry>
<entry>130 &plusmn; 32</entry>
</row>
<row>
<entry>Rr</entry>
<entry>&ensp;18 &plusmn; 8.3&thinsp;</entry>
<entry>220 &plusmn; 32</entry>
<entry>50*</entry>
</row>
<row><entry namest="1" nameend="5" align="center" rowsep="1"></entry>
</row>
<row>
<entry namest="1" nameend="5" align="left"><footnote id="FOO-00001">*From Wood et al (1988) </footnote></entry>
</row>
</tbody>
</tgroup>
</table>
</table-cwu>
</paragraph>
<paragraph id="P-0045" lvl="7"><number>&lsqb;0045&rsqb;</number> Cz: Capsazepine; Rr: Ruthenium red; (CHO): in CHO cells </paragraph>
</section>
</detailed-description>
</subdoc-description>
<sequence-cwu id="SEQLST-1">
<number>1</number>
<sequence-list-new-rules>
<s100>
<s160>4 </s160>
</s100>
<s200>
<s210>1 </s210>
<s211>3463 </s211>
<s212>DNA </s212>
<s213>Homo sapiens </s213>
<s220>
<s221>CDS </s221>
<s222>(359)..(2875) </s222>
</s220>
</s200>
<s400> 1 
ccccccagtt ttacactttt acttcccggt cgtatattgt gtgaaattgt gagcggaata     60 
cccattttca cacaaggaac cagtttatcc tttgattacg ccaagctcga aattaccccc    120 
tcattaaaag ggaacaaaag ttggagctcg cgcgcctgca ggtcgacact agtggatcca    180 
aagaattcgg cacgagccgg gcccgggacc ccacggaggc ggggagacca ctcttctccc    240 
acacgagccc agctctccct tcgagtagca accgccttca agctcacaag cacccgtggg    300 
cctggggtgt gcctgcgtct agctggttgc acactgggcc acagaggatc cagcaagg      358 
atg aag aaa tgg agc agc aca gac ttg ggg gca gct gcg gac cca ctc      406 
Met Lys Lys Trp Ser Ser Thr Asp Leu Gly Ala Ala Ala Asp Pro Leu 
  1               5                  10                  15 
caa aag gac acc tgc cca gac ccc ctg gat gga gac cct aac tcc agg      454 
Gln Lys Asp Thr Cys Pro Asp Pro Leu Asp Gly Asp Pro Asn Ser Arg 
             20                  25                  30 
cca cct cca gcc aag ccc cag ctc tcc acg gcc aag agc cgc acc cgg      502 
Pro Pro Pro Ala Lys Pro Gln Leu Ser Thr Ala Lys Ser Arg Thr Arg 
         35                  40                  45 
ctc ttt ggg aag ggt gac tcg gag gag gct ttc ccg gtg gat tgc cct      550 
Leu Phe Gly Lys Gly Asp Ser Glu Glu Ala Phe Pro Val Asp Cys Pro 
     50                  55                  60 
cac gag gaa ggt gag ctg gac tcc tgc ccg acc atc aca gtc agc cct      598 
His Glu Glu Gly Glu Leu Asp Ser Cys Pro Thr Ile Thr Val Ser Pro 
 65                  70                  75                  80 
gtt atc acc atc cag agg cca gga gac ggc ccc acc ggt gcc agg ctg      646 
Val Ile Thr Ile Gln Arg Pro Gly Asp Gly Pro Thr Gly Ala Arg Leu 
                 85                  90                  95 
ctg tcc cag gac tct gtc gcc gcc agc acc gag aag acc ctc agg ctc      694 
Leu Ser Gln Asp Ser Val Ala Ala Ser Thr Glu Lys Thr Leu Arg Leu 
            100                 105                 110 
tat gat cgc agg agt atc ttt gaa gcc gtt gct cag aat aac tgc cag      742 
Tyr Asp Arg Arg Ser Ile Phe Glu Ala Val Ala Gln Asn Asn Cys Gln 
        115                 120                 125 
gat ctg gag agc ctg ctg ctc ttc ctg cag aag agc aag aag cac ctc      790 
Asp Leu Glu Ser Leu Leu Leu Phe Leu Gln Lys Ser Lys Lys His Leu 
    130                 135                 140 
aca gac aac gag ttc aaa gac cct gag aca ggg aag acc tgt ctg ctg      838 
Thr Asp Asn Glu Phe Lys Asp Pro Glu Thr Gly Lys Thr Cys Leu Leu 
145                 150                 155                 160 
aaa gcc atg ctc aac ctg cac gac gga cag aac acc acc atc ccc ctg      886 
Lys Ala Met Leu Asn Leu His Asp Gly Gln Asn Thr Thr Ile Pro Leu 
                165                 170                 175 
ctc ctg gag atc gcg cgg caa acg gac agc ctg aag gag ctt gtc aac      934 
Leu Leu Glu Ile Ala Arg Gln Thr Asp Ser Leu Lys Glu Leu Val Asn 
            180                 185                 190 
gcc agc tac acg gac agc tac tac aag ggc cag aca gca ctg cac atc      982 
Ala Ser Tyr Thr Asp Ser Tyr Tyr Lys Gly Gln Thr Ala Leu His Ile 
        195                 200                 205 
gcc atc gag aga cgc aac atg gcc ctg gtg acc ctc ctg gtg gag aac     1030 
Ala Ile Glu Arg Arg Asn Met Ala Leu Val Thr Leu Leu Val Glu Asn 
    210                 215                 220 
gga gca gac gtc cag gct gcg gcc cat ggg gac ttc ttt aag aaa acc     1078 
Gly Ala Asp Val Gln Ala Ala Ala His Gly Asp Phe Phe Lys Lys Thr 
225                 230                 235                 240 
aaa ggg cgg cct gga ttc tac ttc ggt gaa ctg ccc ctg tcc ctg gcc     1126 
Lys Gly Arg Pro Gly Phe Tyr Phe Gly Glu Leu Pro Leu Ser Leu Ala 
                245                 250                 255 
gcg tgc acc aac cag ctg ggc atc gtg aag ttc ctg ctg cag aac tcc     1174 
Ala Cys Thr Asn Gln Leu Gly Ile Val Lys Phe Leu Leu Gln Asn Ser 
            260                 265                 270 
tgg cag acg gcc gac atc agc gcc agg gac tcg gtg ggc aac acg gtg     1222 
Trp Gln Thr Ala Asp Ile Ser Ala Arg Asp Ser Val Gly Asn Thr Val 
        275                 280                 285 
ctg cac gcc ctg gtg gag gtg gcc gac aac acg gcc gac aac acg aag     1270 
Leu His Ala Leu Val Glu Val Ala Asp Asn Thr Ala Asp Asn Thr Lys 
    290                 295                 300 
ttt gtg acg agc atg tac aat gag att ctg atc ctg ggg gcc aaa ctg     1318 
Phe Val Thr Ser Met Tyr Asn Glu Ile Leu Ile Leu Gly Ala Lys Leu 
305                 310                 315                 320 
cac ccg acg ctg aag ctg gag gag ctc acc aac aag aag gga atg atg     1366 
His Pro Thr Leu Lys Leu Glu Glu Leu Thr Asn Lys Lys Gly Met Met 
                325                 330                 335 
ccg ctg gct ctg gca gct ggg acc ggg aag atc ggg gtc ttg gcc tat     1414 
Pro Leu Ala Leu Ala Ala Gly Thr Gly Lys Ile Gly Val Leu Ala Tyr 
            340                 345                 350 
att ctc cag cgg gag atc cag gag ccc gag tgc agg cac ctg tcc agg     1462 
Ile Leu Gln Arg Glu Ile Gln Glu Pro Glu Cys Arg His Leu Ser Arg 
        355                 360                 365 
aag ttc acc gag tgg gcc tac ggg ccc gtg cac tcc tcg ctg tac gac     1510 
Lys Phe Thr Glu Trp Ala Tyr Gly Pro Val His Ser Ser Leu Tyr Asp 
    370                 375                 380 
ctg tcc tgc atc gac acc tgc gag aag aac tcg gtg ctg gag gtg atc     1558 
Leu Ser Cys Ile Asp Thr Cys Glu Lys Asn Ser Val Leu Glu Val Ile 
385                 390                 395                 400 
gcc tac agc agc agc gag acc cct aat cgc cac gac atg ctc ttg gtg     1606 
Ala Tyr Ser Ser Ser Glu Thr Pro Asn Arg His Asp Met Leu Leu Val 
                405                 410                 415 
gag ccg ctg aac cga ctc ctg cag gac aag tgg gac aga ttc gtc aag     1654 
Glu Pro Leu Asn Arg Leu Leu Gln Asp Lys Trp Asp Arg Phe Val Lys 
            420                 425                 430 
cgc atc ttc tac ttc aac ttc ctg gtc tac tgc ctg tac atg atc atc     1702 
Arg Ile Phe Tyr Phe Asn Phe Leu Val Tyr Cys Leu Tyr Met Ile Ile 
        435                 440                 445 
ttc acc atg gct gcc tac tac agg ccc gtg gat ggc ttg cct ccc ttt     1750 
Phe Thr Met Ala Ala Tyr Tyr Arg Pro Val Asp Gly Leu Pro Pro Phe 
    450                 455                 460 
aag atg gaa aaa act gga gac tat ttc cga gtt act gga gag atc ctg     1798 
Lys Met Glu Lys Thr Gly Asp Tyr Phe Arg Val Thr Gly Glu Ile Leu 
465                 470                 475                 480 
tct gtg tta gga gga gtc tac ttc ttt ttc cga ggg att cag tat ttc     1846 
Ser Val Leu Gly Gly Val Tyr Phe Phe Phe Arg Gly Ile Gln Tyr Phe 
                485                 490                 495 
ctg cag agg cgg ccg tcg atg aag acc ctg ttt gtg gac agc tac agt     1894 
Leu Gln Arg Arg Pro Ser Met Lys Thr Leu Phe Val Asp Ser Tyr Ser 
            500                 505                 510 
gag atg ctt ttc ttt ctg cag tca ctg ttc atg ctg gcc acc gtg gtg     1942 
Glu Met Leu Phe Phe Leu Gln Ser Leu Phe Met Leu Ala Thr Val Val 
        515                 520                 525 
ctg tac ttc agc cac ctc aag gag tat gtg gct tcc atg gta ttc tcc     1990 
Leu Tyr Phe Ser His Leu Lys Glu Tyr Val Ala Ser Met Val Phe Ser 
    530                 535                 540 
ctg gcc ttg ggc tgg acc aac atg ctc tac tac acc cgc ggt ttc cag     2038 
Leu Ala Leu Gly Trp Thr Asn Met Leu Tyr Tyr Thr Arg Gly Phe Gln 
545                 550                 555                 560 
cag atg ggc atc tat gcc gtc atg ata gag aag atg atc ctg aga gac     2086 
Gln Met Gly Ile Tyr Ala Val Met Ile Glu Lys Met Ile Leu Arg Asp 
                565                 570                 575 
ctg tgc cgt ttc atg ttt gtc tac atc gtc ttc ttg ttc ggg ttt tcc     2134 
Leu Cys Arg Phe Met Phe Val Tyr Ile Val Phe Leu Phe Gly Phe Ser 
            580                 585                 590 
aca gcg gtg gtg acg ctg att gaa gac ggg aag aat gac tcc ctg ccg     2182 
Thr Ala Val Val Thr Leu Ile Glu Asp Gly Lys Asn Asp Ser Leu Pro 
        595                 600                 605 
tct gag tcc acg tcg cac agg tgg cgg ggg cct gcc tgc agg ccc ccc     2230 
Ser Glu Ser Thr Ser His Arg Trp Arg Gly Pro Ala Cys Arg Pro Pro 
    610                 615                 620 
gat agc tcc tac aac agc ctg tac tcc acc tgc ctg gag ctg ttc aag     2278 
Asp Ser Ser Tyr Asn Ser Leu Tyr Ser Thr Cys Leu Glu Leu Phe Lys 
625                 630                 635                 640 
ttc acc atc ggc atg ggc gac ctg gag ttc act gag aac tat gac ttc     2326 
Phe Thr Ile Gly Met Gly Asp Leu Glu Phe Thr Glu Asn Tyr Asp Phe 
                645                 650                 655 
aag gct gtc ttc atc atc ctg ctg ctg gcc tat gta att ctc acc tac     2374 
Lys Ala Val Phe Ile Ile Leu Leu Leu Ala Tyr Val Ile Leu Thr Tyr 
            660                 665                 670 
atc ctc ctg ctc aac atg ctc atc gcc ctc atg ggt gag act gtc aac     2422 
Ile Leu Leu Leu Asn Met Leu Ile Ala Leu Met Gly Glu Thr Val Asn 
        675                 680                 685 
aag atc gca cag gag agc aag aac atc tgg aag ctg cag aga gcc atc     2470 
Lys Ile Ala Gln Glu Ser Lys Asn Ile Trp Lys Leu Gln Arg Ala Ile 
    690                 695                 700 
acc atc ctg gac acg gag aag agc ttc ctt aag tgc atg agg aag gcc     2518 
Thr Ile Leu Asp Thr Glu Lys Ser Phe Leu Lys Cys Met Arg Lys Ala 
705                 710                 715                 720 
ttc cgc tca ggc aag ctg ctg cag gtg ggg tac aca cct gat ggc aag     2566 
Phe Arg Ser Gly Lys Leu Leu Gln Val Gly Tyr Thr Pro Asp Gly Lys 
                725                 730                 735 
gac gac tac cgg tgg tgc ttc agg gtg gac gag gtg aac tgg acc acc     2614 
Asp Asp Tyr Arg Trp Cys Phe Arg Val Asp Glu Val Asn Trp Thr Thr 
            740                 745                 750 
tgg aac acc aac gtg ggc atc atc aac gaa gac ccg ggc aac tgt gag     2662 
Trp Asn Thr Asn Val Gly Ile Ile Asn Glu Asp Pro Gly Asn Cys Glu 
        755                 760                 765 
ggc gtc aag cgc acc ctg agc ttc tcc ctg cgg tca agc aga gtt tca     2710 
Gly Val Lys Arg Thr Leu Ser Phe Ser Leu Arg Ser Ser Arg Val Ser 
    770                 775                 780 
ggc aga cac tgg aag aac ttt gcc ctg gtc ccc ctt tta aga gag gca     2758 
Gly Arg His Trp Lys Asn Phe Ala Leu Val Pro Leu Leu Arg Glu Ala 
785                 790                 795                 800 
agt gct cga gat agg cag tct gct cag ccc gag gaa gtt tat ctg cga     2806 
Ser Ala Arg Asp Arg Gln Ser Ala Gln Pro Glu Glu Val Tyr Leu Arg 
                805                 810                 815 
cag ttt tca ggg tct ctg aag cca gag gac gct gag gtc ttc aag agt     2854 
Gln Phe Ser Gly Ser Leu Lys Pro Glu Asp Ala Glu Val Phe Lys Ser 
            820                 825                 830 
cct gcc gct tcc ggg gag aag tgaggacgtc acgcagacag cactgtcaac        2905 
Pro Ala Ala Ser Gly Glu Lys 
        835 
actgggcctt aggagacccc gttgccacgg ggggctgctg agggaacacc agtgctctgt   2965 
cagcagcctg gcctggtctg tgcctgccca gcatgttccc aaatctgtgc tggacaaact   3025 
gtgggaaagc gttcttggaa gcatggggag tgatgtacat ccaaccgtca ctgtccccaa   3085 
gtgaatctcc taacagactt tcaggttttt actcacttta ctaaacagtg tggatggtca   3145 
gtctctactg ggacatgtta ggcccttgtt ttctttgatt ttattctttt ttttgagaca   3205 
gaatttcact cttctcgccc aggctggaat gcagtggcac aattttggct ccctgcaacc   3265 
tccgcctcct ggattccagc aattctcctg cctcggcttc ccaagtagct gggattacag   3325 
gcacgtgcca ccatgtctgg ctaatttttt ggattttttt aataaaaatg ggggttcgcc   3385 
atgttggcca ggctggtctc gaactcctga ccttagggga tccccccacc ttgggcctcc   3445 
caaagggctg ggaataca                                                 3463 
</s400>
<s200>
<s210>2 </s210>
<s211>839 </s211>
<s212>PRT </s212>
<s213>Homo sapiens </s213>
</s200>
<s400> 2 
Met Lys Lys Trp Ser Ser Thr Asp Leu Gly Ala Ala Ala Asp Pro Leu 
  1               5                  10                  15 
Gln Lys Asp Thr Cys Pro Asp Pro Leu Asp Gly Asp Pro Asn Ser Arg 
             20                  25                  30 
Pro Pro Pro Ala Lys Pro Gln Leu Ser Thr Ala Lys Ser Arg Thr Arg 
         35                  40                  45 
Leu Phe Gly Lys Gly Asp Ser Glu Glu Ala Phe Pro Val Asp Cys Pro 
     50                  55                  60 
His Glu Glu Gly Glu Leu Asp Ser Cys Pro Thr Ile Thr Val Ser Pro 
 65                  70                  75                  80 
Val Ile Thr Ile Gln Arg Pro Gly Asp Gly Pro Thr Gly Ala Arg Leu 
                 85                  90                  95 
Leu Ser Gln Asp Ser Val Ala Ala Ser Thr Glu Lys Thr Leu Arg Leu 
            100                 105                 110 
Tyr Asp Arg Arg Ser Ile Phe Glu Ala Val Ala Gln Asn Asn Cys Gln 
        115                 120                 125 
Asp Leu Glu Ser Leu Leu Leu Phe Leu Gln Lys Ser Lys Lys His Leu 
    130                 135                 140 
Thr Asp Asn Glu Phe Lys Asp Pro Glu Thr Gly Lys Thr Cys Leu Leu 
145                 150                 155                 160 
Lys Ala Met Leu Asn Leu His Asp Gly Gln Asn Thr Thr Ile Pro Leu 
                165                 170                 175 
Leu Leu Glu Ile Ala Arg Gln Thr Asp Ser Leu Lys Glu Leu Val Asn 
            180                 185                 190 
Ala Ser Tyr Thr Asp Ser Tyr Tyr Lys Gly Gln Thr Ala Leu His Ile 
        195                 200                 205 
Ala Ile Glu Arg Arg Asn Met Ala Leu Val Thr Leu Leu Val Glu Asn 
    210                 215                 220 
Gly Ala Asp Val Gln Ala Ala Ala His Gly Asp Phe Phe Lys Lys Thr 
225                 230                 235                 240 
Lys Gly Arg Pro Gly Phe Tyr Phe Gly Glu Leu Pro Leu Ser Leu Ala 
                245                 250                 255 
Ala Cys Thr Asn Gln Leu Gly Ile Val Lys Phe Leu Leu Gln Asn Ser 
            260                 265                 270 
Trp Gln Thr Ala Asp Ile Ser Ala Arg Asp Ser Val Gly Asn Thr Val 
        275                 280                 285 
Leu His Ala Leu Val Glu Val Ala Asp Asn Thr Ala Asp Asn Thr Lys 
    290                 295                 300 
Phe Val Thr Ser Met Tyr Asn Glu Ile Leu Ile Leu Gly Ala Lys Leu 
305                 310                 315                 320 
His Pro Thr Leu Lys Leu Glu Glu Leu Thr Asn Lys Lys Gly Met Met 
                325                 330                 335 
Pro Leu Ala Leu Ala Ala Gly Thr Gly Lys Ile Gly Val Leu Ala Tyr 
            340                 345                 350 
Ile Leu Gln Arg Glu Ile Gln Glu Pro Glu Cys Arg His Leu Ser Arg 
        355                 360                 365 
Lys Phe Thr Glu Trp Ala Tyr Gly Pro Val His Ser Ser Leu Tyr Asp 
    370                 375                 380 
Leu Ser Cys Ile Asp Thr Cys Glu Lys Asn Ser Val Leu Glu Val Ile 
385                 390                 395                 400 
Ala Tyr Ser Ser Ser Glu Thr Pro Asn Arg His Asp Met Leu Leu Val 
                405                 410                 415 
Glu Pro Leu Asn Arg Leu Leu Gln Asp Lys Trp Asp Arg Phe Val Lys 
            420                 425                 430 
Arg Ile Phe Tyr Phe Asn Phe Leu Val Tyr Cys Leu Tyr Met Ile Ile 
        435                 440                 445 
Phe Thr Met Ala Ala Tyr Tyr Arg Pro Val Asp Gly Leu Pro Pro Phe 
    450                 455                 460 
Lys Met Glu Lys Thr Gly Asp Tyr Phe Arg Val Thr Gly Glu Ile Leu 
465                 470                 475                 480 
Ser Val Leu Gly Gly Val Tyr Phe Phe Phe Arg Gly Ile Gln Tyr Phe 
                485                 490                 495 
Leu Gln Arg Arg Pro Ser Met Lys Thr Leu Phe Val Asp Ser Tyr Ser 
            500                 505                 510 
Glu Met Leu Phe Phe Leu Gln Ser Leu Phe Met Leu Ala Thr Val Val 
        515                 520                 525 
Leu Tyr Phe Ser His Leu Lys Glu Tyr Val Ala Ser Met Val Phe Ser 
    530                 535                 540 
Leu Ala Leu Gly Trp Thr Asn Met Leu Tyr Tyr Thr Arg Gly Phe Gln 
545                 550                 555                 560 
Gln Met Gly Ile Tyr Ala Val Met Ile Glu Lys Met Ile Leu Arg Asp 
                565                 570                 575 
Leu Cys Arg Phe Met Phe Val Tyr Ile Val Phe Leu Phe Gly Phe Ser 
            580                 585                 590 
Thr Ala Val Val Thr Leu Ile Glu Asp Gly Lys Asn Asp Ser Leu Pro 
        595                 600                 605 
Ser Glu Ser Thr Ser His Arg Trp Arg Gly Pro Ala Cys Arg Pro Pro 
    610                 615                 620 
Asp Ser Ser Tyr Asn Ser Leu Tyr Ser Thr Cys Leu Glu Leu Phe Lys 
625                 630                 635                 640 
Phe Thr Ile Gly Met Gly Asp Leu Glu Phe Thr Glu Asn Tyr Asp Phe 
                645                 650                 655 
Lys Ala Val Phe Ile Ile Leu Leu Leu Ala Tyr Val Ile Leu Thr Tyr 
            660                 665                 670 
Ile Leu Leu Leu Asn Met Leu Ile Ala Leu Met Gly Glu Thr Val Asn 
        675                 680                 685 
Lys Ile Ala Gln Glu Ser Lys Asn Ile Trp Lys Leu Gln Arg Ala Ile 
    690                 695                 700 
Thr Ile Leu Asp Thr Glu Lys Ser Phe Leu Lys Cys Met Arg Lys Ala 
705                 710                 715                 720 
Phe Arg Ser Gly Lys Leu Leu Gln Val Gly Tyr Thr Pro Asp Gly Lys 
                725                 730                 735 
Asp Asp Tyr Arg Trp Cys Phe Arg Val Asp Glu Val Asn Trp Thr Thr 
            740                 745                 750 
Trp Asn Thr Asn Val Gly Ile Ile Asn Glu Asp Pro Gly Asn Cys Glu 
        755                 760                 765 
Gly Val Lys Arg Thr Leu Ser Phe Ser Leu Arg Ser Ser Arg Val Ser 
    770                 775                 780 
Gly Arg His Trp Lys Asn Phe Ala Leu Val Pro Leu Leu Arg Glu Ala 
785                 790                 795                 800 
Ser Ala Arg Asp Arg Gln Ser Ala Gln Pro Glu Glu Val Tyr Leu Arg 
                805                 810                 815 
Gln Phe Ser Gly Ser Leu Lys Pro Glu Asp Ala Glu Val Phe Lys Ser 
            820                 825                 830 
Pro Ala Ala Ser Gly Glu Lys 
        835 
</s400>
<s200>
<s210>3 </s210>
<s211>5155 </s211>
<s212>DNA </s212>
<s213>Homo sapiens </s213>
</s200>
<s400> 3 
aagctttttg caaaagccta ggaaaaaagc ctcctcacta cttctggaat agctcagagg     60 
ccgaggcggc ctcggcctct gcataaataa aaaaaattag tcagccatgg ggcggagaat    120 
gggcggaact gggcggagtt aggggcggga tgggcggagt taggggcggg actatggttg    180 
ctgactaatt gagatgcatg ctttgcatac ttctgcctgc tggggagcct ggggactttc    240 
cacacctggt tgctgactaa ttgagatgca tgctttgcat acttctgcct gctggggagc    300 
ctggggactt tccacaccct aactgacaca cattccacag gatccggtcg cgcgaatttc    360 
gagcggtgtt ccgcggtcct cctcgtatag aaactcggac cactctgaga cgaaggctcg    420 
cgtccaggcc agcacgaagg aggctaagtg ggaggggtag cggtcgttgt ccactagggg    480 
gtccactcgc tccagggtgt gaagacacat gtcgccctct tcggcatcaa ggaaggtgat    540 
tggtttatag gtgtaggcca cgtgaccggg tgttcctgaa ggggggctat aaaagggggt    600 
gggggcgcgt tcgtcctcac tctcttccgc atcgctgtct gcgagggcca gctgttgggc    660 
tcgcggttga ggacaaactc ttcgcggtct ttccagtact cttggatcgg aaacccgtcg    720 
gcctccgaac ggtactccgc caccgaggga cctgagcgag tccgcatcga ccggatcgga    780 
aaacctctcg actgttgggg tgagtactcc ctctcaaaag cgggcatgac ttctgcgcta    840 
agattgtcag tttccaaaaa cgaggaggat ttgatattca cctggcccgc ggtgatgcct    900 
ttgagggtgg ccgcgtccat ctggtcagaa aagacaatct ttttgttgtc aagcttgagg    960 
tgtggcaggc ttgagatctg gccatacact tgagtgacaa tgacatccac tttgcctttc   1020 
tctccacagg tgtccactcc caggtccaac tgcaggtcga ctctagagga tccccgggta   1080 
ccgagctcga attccggggg gggggggggg ggggacagct cagggctgcg atttcgcgcc   1140 
aaacttgacg gcaatcctag cgtgaaggct ggtaggattt tatccccgct gccatcatgg   1200 
ttcgaccatt gaactgcatc gtcgccgtgt cccaaaatat ggggattggc aagaacggag   1260 
acctaccctg gcctccgctc aggaacgagt tcaagtactt ccaaagaatg accacaacct   1320 
cttcagtgga aggtaaacag aatctggtga ttatgggtag gaaaacctgg ttctccattc   1380 
ctgagaagaa tcgaccttta aaggacagaa ttaatatagt tctcagtaga gaactcaaag   1440 
aaccaccacg aggagctcat tttcttgcca aaagtttgga tgatgcctta agacttattg   1500 
aacaaccgga attggcaagt aaagtagaca tggtttggat agtcggaggc agttctgttt   1560 
accaggaagc catgaatcaa ccaggccacc tcagactctt tgtgacaagg atcatgcagg   1620 
aatttgaaag tgacacgttt ttcccagaaa ttgatttggg gaaatataaa cttctcccag   1680 
aatacccagg cgtcctctct gaggtccagg aggaaaaagg catcaagtat aagtttgaag   1740 
tctacgagaa gaaagactaa caggaagatg ctttcaagtt ctctgctccc ctcctaaagc   1800 
tatgcatttt ttataagacc atgggacttt tgctggcttt agatcataat cagccatacc   1860 
acatttgtag aggttttact tgctttaaaa aacctcccac acctccccct gaacctgaaa   1920 
cataaaatga atgcaattgt tgttgttaac ttgtttattg cagcttataa tggttacaaa   1980 
taaagcaata gcatcacaaa tttcacaaat aaagcatttt tttcactgca ttctagttgt   2040 
ggtttgtcca aactcatcaa tgtatcttat catgtctgga tccccggcca acggtctggt   2100 
gacccggctg cgagagctcg gtgtacctga gacgcgagta agcccttgag tcaaagacgt   2160 
agtcgttgca agtccgcacc aggtactgat atcccaccaa aaagtgcggc ggcggctggc   2220 
ggtagagggg ccagcgtagg gtggccgggg ctccgggggc gaggtcttcc aacataaggc   2280 
gatgatatcc gtagatgtac ctggacatcc aggtgatgcc ggcggcggtg gtggaggcgc   2340 
gcggaaagtc gcggacgcgg ttccagatgt tgcgcagcgg caaaaagtgc tccatggtcg   2400 
ggacgctctg gccggtgagg cgtgcgcagt cgttgacgct ctagaccgtg caaaaggaga   2460 
gcctgtaagc gggcactctt ccgtggtctg gtggataaat tcgcaagggt atcatggcgg   2520 
acgaccgggg ttcgaacccc ggatccggcc gtccgccgtg atccatccgg ttaccgcccg   2580 
cgtgtcgaac ccaggtgtgc gacgtcagac aacgggggag cgctcctttt ggcttccttc   2640 
caggcgcggc ggctgctgcg ctagcttttt tggcgagctc gaattaattc tgcattaatg   2700 
aatcggccaa cgcgcgggga gaggcggttt gcgtattggg cgctcttccg cttcctcgct   2760 
cactgactcg ctgcgctcgg tcgttcggct gcggcgagcg gtatcagctc actcaaaggc   2820 
ggtaatacgg ttatccacag aatcagggga taacgcagga aagaacatgt gagcaaaagg   2880 
ccagcaaaag gccaggaacc gtaaaaaggc cgcgttgctg gcgtttttcc ataggctccg   2940 
cccccctgac gagcatcaca aaaatcgacg ctcaagtcag aggtggcgaa acccgacagg   3000 
actataaaga taccaggcgt ttccccctgg aagctccctc gtgcgctctc ctgttccgac   3060 
cctgccgctt accggatacc tgtccgcctt tctcccttcg ggaagcgtgg cgctttctca   3120 
atgctcacgc tgtaggtatc tcagttcggt gtaggtcgtt cgctccaagc tgggctgtgt   3180 
gcacgaaccc cccgttcagc ccgaccgctg cgccttatcc ggtaactatc gtcttgagtc   3240 
caacccggta agacacgact tatcgccact ggcagcagcc actggtaaca ggattagcag   3300 
agcgaggtat gtaggcggtg ctacagagtt cttgaagtgg tggcctaact acggctacac   3360 
tagaaggaca gtatttggta tctgcgctct gctgaagcca gttaccttcg gaaaaagagt   3420 
tggtagctct tgatccggca aacaaaccac cgctggtagc ggtggttttt ttgtttgcaa   3480 
gcagcagatt acgcgcagaa aaaaaggatc tcaagaagat cctttgatct tttctacggg   3540 
gtctgacgct cagtggaacg aaaactcacg ttaagggatt ttggtcatga gattatcaaa   3600 
aaggatcttc acctagatcc ttttaaatta aaaatgaagt tttaaatcaa tctaaagtat   3660 
atatgagtaa acttggtctg acagttacca atgcttaatc agtgaggcac ctatctcagc   3720 
gatctgtcta tttcgttcat ccatagttgc ctgactcccc gtcgtgtaga taactacgat   3780 
acgggagggc ttaccatctg gccccagtgc tgcaatgata ccgcgagacc cacgctcacc   3840 
ggctccagat ttatcagcaa taaaccagcc agccggaagg gccgagcgca gaagtggtcc   3900 
tgcaacttta tccgcctcca tccagtctat taattgttgc cgggaagcta gagtaagtag   3960 
ttcgccagtt aatagtttgc gcaacgttgt tgccattgct acaggcatcg tggtgtcacg   4020 
ctcgtcgttt ggtatggctt cattcagctc cggttcccaa cgatcaaggc gagttacatg   4080 
atcccccatg ttgtgcaaaa aagcggttag ctccttcggt cctccgatcg ttgtcagaag   4140 
taagttggcc gcagtgttat cactcatggt tatggcagca ctgcataatt ctcttactgt   4200 
catgccatcc gtaagatgct tttctgtgac tggtgagtac tcaaccaagt cattctgaga   4260 
atagtgtatg cggcgaccga gttgctcttg cccggcgtca atacgggata ataccgcgcc   4320 
acatagcaga actttaaaag tgctcatcat tggaaaacgt tcttcggggc gaaaactctc   4380 
aaggatctta ccgctgttga gatccagttc gatgtaaccc actcgtgcac ccaactgatc   4440 
ttcagcatct tttactttca ccagcgtttc tgggtgagca aaaacaggaa ggcaaaatgc   4500 
cgcaaaaaag ggaataaggg cgacacggaa atgttgaata ctcatactct tcctttttca   4560 
atattattga agcatttatc agggttattg tctcatgagc ggatacatat ttgaatgtat   4620 
ttagaaaaat aaacaaatag gggttccgcg cacatttccc cgaaaagtgc cacctgacgt   4680 
ctaagaaacc attattatca tgacattaac ctataaaaat aggcgtatca cgaggccctt   4740 
tcgtctcgcg cgtttcggtg atgacggtga aaacctctga cacatgcagc tcccggagac   4800 
ggtcacagct tgtctgtaag cggatgccgg gagcagacaa gcccgtcagg gcgcgtcagc   4860 
gggtgttggc gggtgtcggg gctggcttaa ctatgcggca tcagagcaga ttgtactgag   4920 
agtgcaccat atgcggtgcg aaataccgca cagatgcgta aggagaaaat accgcatcag   4980 
gcgccattcg ccattcaggc tgcgcaactg ttgggaaggg cgatcggtgc gggcctcttc   5040 
gctattacgc cagctggcga aagggggatg tgctgcaagg cgattaagtt gggtaacgcc   5100 
agggttttcc cagtcacgac gttgtaaaac gacggccagt gccaagcttt ttgca        5155 
</s400>
<s200>
<s210>4 </s210>
<s211>4886 </s211>
<s212>DNA </s212>
<s213>Homo sapiens </s213>
</s200>
<s400> 4 
ctagcatgca gtcaagctta catcagactt cgacaaccca agatggattg gacgacacaa     60 
gcatatgttc aatttccttg atgtcaacca caatggaaaa atctctcttg acgagatggt    120 
ctacaaggca tctgatattg tcatcaataa ccttggagca acacctgagc aagccaaacg    180 
acacaaagat gctgtagaag ccttcttcgg aggagctgga atgaaatatg gtgtggaaac    240 
tgattggcct gcatatattg aaggatggaa aaaattggct actgatgaat tggagaaata    300 
cgccaaaaac gaaccaacgc tcatccgtat atggggtgat gctttgtttg atatcgttga    360 
caaagatcaa aatggagcca ttacactgga tgaatggaaa gcatacacca aagctgctgg    420 
tatcatccaa tcatcagaag attgcgagga aacattcaga gtgtgcgata ttgatgaaag    480 
tggacaactc gatgttgatg agatgacaag acaacattta ggattttggt acaccatgga    540 
tcctgcttgc gaaaagctct acggtggagc tgtcccctaa gaagaattca aaaagcttct    600 
cgagagtact tctagagcgg ccgcgggccc atcgattttc cacccgggtg gggtaccagg    660 
taagtgtacc caattcgccc tatagtgagt cgtattacaa ttcactggcc gtcgttttac    720 
aacgtcgtga ctgggaaaac cctggcgtta cccaacttaa tcgccttgca gcacatcccc    780 
ctttcgccag ctggcgtaat agcgaagagg cccgcaccga tcgcccttcc caacagttgc    840 
gcagcctgaa tggcgaatgg agatccaatt tttaagtgta taatgtgtta aactactgat    900 
tctaattgtt tgtgtatttt agattcacag tcccaaggct catttcaggc ccctcagtcc    960 
tcacagtctg ttcatgatca taatcagcca taccacattt gtagaggttt tacttgcttt   1020 
aaaaaacctc ccacacctcc ccctgaacct gaaacataaa atgaatgcaa ttgttgttgt   1080 
taacttgttt attgcagctt ataatggtta caaataaagc aatagcatca caaatttcac   1140 
aaataaagca tttttttcac tgcattctag ttgtggtttg tccaaactca tcaatgtatc   1200 
ttaacgcgta aattgtaagc gttaatattt tgttaaaatt cgcgttaaat ttttgttaaa   1260 
tcagctcatt ttttaaccaa taggccgaaa tcggcaaaat cccttataaa tcaaaagaat   1320 
agaccgagat agggttgagt gttgttccag tttggaacaa gagtccacta ttaaagaacg   1380 
tggactccaa cgtcaaaggg cgaaaaaccg tctatcaggg cgatggccca ctacgtgaac   1440 
catcacccta atcaagtttt ttggggtcga ggtgccgtaa agcactaaat cggaacccta   1500 
aagggagccc ccgatttaga gcttgacggg gaaagccggc gaacgtggcg agaaaggaag   1560 
ggaagaaagc gaaaggagcg ggcgctaggg cgctggcaag tgtagcggtc acgctgcgcg   1620 
taaccaccac acccgccgcg cttaatgcgc cgctacaggg cgcgtcaggt ggcacttttc   1680 
ggggaaatgt gcgcggaacc cctatttgtt tatttttcta aatacattca aatatgtatc   1740 
cgctcatgag acaataaccc tgataaatgc ttcaataata ttgaaaaagg aagagtcctg   1800 
aggcggaaag aaccagctgt ggaatgtgtg tcagttaggg tgtggaaagt ccccaggctc   1860 
cccagcaggc agaagtatgc aaagcatgca tctcaattag tcagcaacca ggtgtggaaa   1920 
gtccccaggc tccccagcag gcagaagtat gcaaagcatg catctcaatt agtcagcaac   1980 
catagtcccg cccctaactc cgcccatccc gcccctaact ccgcccagtt ccgcccattc   2040 
tccgccccat ggctgactaa ttttttttat ttatgcagag gccgaggccg cctcggcctc   2100 
tgagctattc cagaagtagt gaggaggctt ttttggaggc ctaggctttt gcaaagatcg   2160 
atcaagagac aggatgagga tcgtttcgca tgattgaaca agatggattg cacgcaggtt   2220 
ctccggccgc ttgggtggag aggctattcg gctatgactg ggcacaacag acaatcggct   2280 
gctctgatgc cgccgtgttc cggctgtcag cgcaggggcg cccggttctt tttgtcaaga   2340 
ccgacctgtc cggtgccctg aatgaactgc aagacgaggc agcgcggcta tcgtggctgg   2400 
ccacgacggg cgttccttgc gcagctgtgc tcgacgttgt cactgaagcg ggaagggact   2460 
ggctgctatt gggcgaagtg ccggggcagg atctcctgtc atctcacctt gctcctgccg   2520 
agaaagtatc catcatggct gatgcaatgc ggcggctgca tacgcttgat ccggctacct   2580 
gcccattcga ccaccaagcg aaacatcgca tcgagcgagc acgtactcgg atggaagccg   2640 
gtcttgtcga tcaggatgat ctggacgaag agcatcaggg gctcgcgcca gccgaactgt   2700 
tcgccaggct caaggcgagc atgcccgacg gcgaggatct cgtcgtgacc catggcgatg   2760 
cctgcttgcc gaatatcatg gtggaaaatg gccgcttttc tggattcatc gactgtggcc   2820 
ggctgggtgt ggcggaccgc tatcaggaca tagcgttggc tacccgtgat attgctgaag   2880 
agcttggcgg cgaatgggct gaccgcttcc tcgtgcttta cggtatcgcc gctcccgatt   2940 
cgcagcgcat cgccttctat cgccttcttg acgagttctt ctgagcggga ctctggggtt   3000 
cgaaatgacc gaccaagcga cgcccaacct gccatcacga gatttcgatt ccaccgccgc   3060 
cttctatgaa aggttgggct tcggaatcgt tttccgggac gccggctgga tgatcctcca   3120 
gcgcggggat ctcatgctgg agttcttcgc ccaccctagg gggaggctaa ctgaaacacg   3180 
gaaggagaca ataccggaag gaacccgcgc tatgacggca ataaaaagac agaataaaac   3240 
gcacggtgtt gggtcgtttg ttcataaacg cggggttcgg tcccagggct ggcactctgt   3300 
cgatacccca ccgagacccc attggggcca atacgcccgc gtttcttcct tttccccacc   3360 
ccacccccca agttcgggtg aaggcccagg gctcgcagcc aacgtcgggg cggcaggccc   3420 
tgccatagcc tcaggttact catatatact ttagattgat ttaaaacttc atttttaatt   3480 
taaaaggatc taggtgaaga tcctttttga taatctcatg accaaaatcc cttaacgtga   3540 
gttttcgttc cactgagcgt cagaccccgt agaaaagatc aaaggatctt cttgagatcc   3600 
tttttttctg cgcgtaatct gctgcttgca aacaaaaaaa ccaccgctac cagcggtggt   3660 
ttgtttgccg gatcaagagc taccaactct ttttccgaag gtaactggct tcagcagagc   3720 
gcagatacca aatactgtcc ttctagtgta gccgtagtta ggccaccact tcaagaactc   3780 
tgtagcaccg cctacatacc tcgctctgct aatcctgtta ccagtggctg ctgccagtgg   3840 
cgataagtcg tgtcttaccg ggttggactc aagacgatag ttaccggata aggcgcagcg   3900 
gtcgggctga acggggggtt cgtgcacaca gcccagcttg gagcgaacga cctacaccga   3960 
actgagatac ctacagcgtg agctatgaga aagcgccacg cttcccgaag ggagaaaggc   4020 
ggacaggtat ccggtaagcg gcagggtcgg aacaggagag cgcacgaggg agcttccagg   4080 
gggaaacgcc tggtatcttt atagtcctgt cgggtttcgc cacctctgac ttgagcgtcg   4140 
atttttgtga tgctcgtcag gggggcggag cctatggaaa aacgccagca acgcggcctt   4200 
tttacggttc ctggcctttt gctggccttt tgctcacatg ttctttcctg cgttatcccc   4260 
tgattctgtg gataaccgta ttaccgccat gcattagtta ttaatagtaa tcaattacgg   4320 
ggtcattagt tcatagccca tatatggagt tccgcgttac ataacttacg gtaaatggcc   4380 
cgcctggctg accgcccaac gacccccgcc cattgacgtc aataatgacg tatgttccca   4440 
tagtaacgcc aatagggact ttccattgac gtcaatgggt ggagtattta cggtaaactg   4500 
cccacttggc agtacatcaa gtgtatcata tgccaagtac gccccctatt gacgtcaatg   4560 
acggtaaatg gcccgcctgg cattatgccc agtacatgac cttatgggac tttcctactt   4620 
ggcagtacat ctacgtatta gtcatcgcta ttaccatggt gatgcggttt tggcagtaca   4680 
tcaatgggcg tggatagcgg tttgactcac ggggatttcc aagtctccac cccattgacg   4740 
tcaatgggag tttgttttgg caccaaaatc aacgggactt tccaaaatgt cgtaacaact   4800 
ccgccccatt gacgcaaatg ggcggtaggc gtgtacggtg ggaggtctat ataagcagag   4860 
ctggtttagt gaaccgtcag atccga                                        4886
</s400>
</sequence-list-new-rules>
</sequence-cwu>
<subdoc-claims>
<heading lvl="1">What is claimed is: </heading>
<claim id="CLM-00001">
<claim-text><highlight><bold>1</bold></highlight>. An isolated nucleic acid encoding a human vanilloid receptor. </claim-text>
</claim>
<claim id="CLM-00002">
<claim-text><highlight><bold>2</bold></highlight>. The nucleic acid of <dependent-claim-reference depends_on="CLM-00001">claim 1</dependent-claim-reference>, wherein the nucleic acid is capable of directing expression of a human vanilloid receptor. </claim-text>
</claim>
<claim id="CLM-00003">
<claim-text><highlight><bold>3</bold></highlight>. The nucleic acid of <dependent-claim-reference depends_on="CLM-00001">claim 1</dependent-claim-reference> wherein the nucleic acid is cDNA and the cDNA is capable of directing expression of a human vanilloid receptor. </claim-text>
</claim>
<claim id="CLM-00004">
<claim-text><highlight><bold>4</bold></highlight>. The cDNA of <dependent-claim-reference depends_on="CLM-00003">claim 3</dependent-claim-reference> wherein the nucleotide sequence of the cDNA has a sequence identity with the nucleotide sequence of SEQ ID NO: 1 of from more than 85.5% to 100%. </claim-text>
</claim>
<claim id="CLM-00005">
<claim-text><highlight><bold>5</bold></highlight>. The cDNA of <dependent-claim-reference depends_on="CLM-00004">claim 4</dependent-claim-reference> wherein the cDNA comprises a nucleic acid identical over the open reading frame to the sequence as described in SEQ ID NO: 1. </claim-text>
</claim>
<claim id="CLM-00006">
<claim-text><highlight><bold>6</bold></highlight>. The cDNA of <dependent-claim-reference depends_on="CLM-00005">claim 5</dependent-claim-reference> capable of directing expression of the predicted protein depicted in SEQ ID NO: 2. </claim-text>
</claim>
<claim id="CLM-00007">
<claim-text><highlight><bold>7</bold></highlight>. A recombinant human vanilloid receptor. </claim-text>
</claim>
<claim id="CLM-00008">
<claim-text><highlight><bold>8</bold></highlight>. The receptor of <dependent-claim-reference depends_on="CLM-00007">claim 7</dependent-claim-reference> encoded by a nucleic acid wherein the nucleic acid has sequence identity of from more than 85.5% to 100% over the open reading frame of SEQ ID NO: 1. </claim-text>
</claim>
<claim id="CLM-00009">
<claim-text><highlight><bold>9</bold></highlight>. The receptor of <dependent-claim-reference depends_on="CLM-00007">claim 7</dependent-claim-reference> comprising an amino acid sequence identical to the sequence of SEQ ID NO: 2. </claim-text>
</claim>
<claim id="CLM-00010">
<claim-text><highlight><bold>10</bold></highlight>. The receptor of <dependent-claim-reference depends_on="CLM-00007">claim 7</dependent-claim-reference> wherein when the receptor is expressed in mammalian cells, the receptor can be activated by capsaicin, in the presence of temperatures greater than 42&deg; C. and by pH less than 5.5. </claim-text>
</claim>
<claim id="CLM-00011">
<claim-text><highlight><bold>11</bold></highlight>. The receptor of <dependent-claim-reference depends_on="CLM-00007">claim 7</dependent-claim-reference> wherein activation by capsaicin, temperatures greater than 42&deg; C. or by pH less than 5.5 is inhibited by the action of the capsaicin antagonist capsazepine. </claim-text>
</claim>
<claim id="CLM-00012">
<claim-text><highlight><bold>12</bold></highlight>. A cell expressing a recombinant human vanilloid receptor. </claim-text>
</claim>
<claim id="CLM-00013">
<claim-text><highlight><bold>13</bold></highlight>. The cell expressing recombinant mammalian vanilloid receptor of <dependent-claim-reference depends_on="CLM-00011">claim 12</dependent-claim-reference> additionally expressing recombinant aequorin. </claim-text>
</claim>
<claim id="CLM-00014">
<claim-text><highlight><bold>14</bold></highlight>. A method for measuring vanilloid receptor activation comprising the steps of: 
<claim-text>producing a cell expressing recombinant mammalian vanilloid receptor and aequorin; and </claim-text>
<claim-text>measuring changes in aequorin luminescence of the cell. </claim-text>
</claim-text>
</claim>
<claim id="CLM-00015">
<claim-text><highlight><bold>15</bold></highlight>. A method for identifying vanilloid receptor channel blockers comprising the steps of: 
<claim-text>incubating a cell expressing a mammalian vanilloid receptor and aequorin with a potential vanilloid receptor channel blocker; </claim-text>
<claim-text>adding an activator/agonist of the vanilloid receptor channel; and </claim-text>
<claim-text>measuring changes in aequorin luminescence. </claim-text>
</claim-text>
</claim>
<claim id="CLM-00016">
<claim-text><highlight><bold>16</bold></highlight>. A method for identifying vanilloid receptor channel agonists comprising the steps of: 
<claim-text>incubating a cell expressing a mammalian vanilloid receptor and aequorin, adding the potential vanilloid receptor channel agonist; and </claim-text>
<claim-text>measuring changes in aequorin luminescence. </claim-text>
</claim-text>
</claim>
<claim id="CLM-00017">
<claim-text><highlight><bold>17</bold></highlight>. A vanilloid receptor channel blocker identified by the method of <dependent-claim-reference depends_on="CLM-00011">claim 15</dependent-claim-reference>. </claim-text>
</claim>
<claim id="CLM-00018">
<claim-text><highlight><bold>18</bold></highlight>. A vanilloid receptor channel agonist identified by the method of <dependent-claim-reference depends_on="CLM-00011">claim 16</dependent-claim-reference>. </claim-text>
</claim>
<claim id="CLM-00019">
<claim-text><highlight><bold>19</bold></highlight>. An isolated human vanilloid receptor.</claim-text>
</claim>
</subdoc-claims>
</patent-application-publication>
